1. Carcinogenicity assessment of daprodustat (GSK1278863), a hypoxia-inducible factor (HIF)-Prolyl hydroxylase inhibitor;Adams;Toxicol. Pathol.,2020
2. Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan;Akizawa;J. Am. Soc. Nephrol.,2020
3. Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long Studies;Akizawa;Ther. Apher. Dial.,2021
4. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial;Akizawa;Clin. J. Am. Soc. Nephrol.,2020
5. Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study;Akizawa;Ther. Apher. Dial.,2020